Methyl Isobutyl Ketone

Methyl Isobutyl Ketone

SCHEMBL163328

CC(=O)CC(C)C.Cc1ccccc1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
TDP1 Q9NUW8 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
ACHE P22303 2/20 0.47
LMNA P02545 3/20 0.46
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
SLC25A5 P05141 1/20 0.46
HPGD P15428 3/20 0.43
RAB9A P51151 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
STAT3 P40763 1/20 0.40
HTT P42858 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Isobutyl Ketone SCHEMBL9328768 0.96 ALDH1A1 (0.54) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
Methyl Isobutyl Ketone SCHEMBL11007468 0.94 ALDH1A1 (0.52) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
Methyl Isobutyl Ketone SCHEMBL8727203 0.94 ALDH1A1 (0.52) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
Methyl Isobutyl Ketone SCHEMBL10487290 0.94 ACHE (0.56) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
P-Xylene SCHEMBL28115019 0.93 TDP1 (0.50) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
Methyl Isobutyl Ketone SCHEMBL11127111 0.91 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
P-Xylene SCHEMBL28174939 0.91 ALDH1A1 (0.48) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
O-Xylene SCHEMBL9644431 0.89 ALDH1A1 (0.47) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
P-Xylene SCHEMBL27317096 0.89 TDP1 (0.67) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT
Methyl Isobutyl Ketone SCHEMBL17510087 0.88 TDP1 (0.45) ALDH1A1TDP1SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115109229-B Anti-yellowing and temperature-resistant tetrafunctional epoxy resin and preparation method thereof 广东诚展科技股份有限公司 2023-09-05 CN claimed
CN-115109229-A Yellowing-resistant and temperature-resistant four-functional-group epoxy resin and preparation method thereof 河源诚展科技有限公司 2022-09-27 CN claimed
CN-108794342-A Ammonium carboxylate salt compound, its crystal form, amorphous substance and preparation method thereof 武汉朗来科技发展有限公司 2018-11-13 CN claimed
US-20070060756-A1 Process for the preparation of desloratadine ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) 2007-03-15 US claimed
JP-6001741-A None JP disclosed
EP-4400498-A1 AMORPHOUS SUBSTANCES, CRYSTALS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES OF THIOHYDANTOIN COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Suzhou Kintor Pharmaceuticals, Inc. (CN) 2024-07-17 EP disclosed
CN-118235089-A Curable resin composition, laminated structure, cured product, and electronic component 太阳控股株式会社 2024-06-21 CN disclosed
US-20240190815-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF SPRINGWORKS THERAPEUTICS, INC. 2024-06-13 US disclosed
CN-113196171-B Curable resin composition, dry film, cured product, and electronic component 太阳控股株式会社 2024-04-23 CN disclosed
CN-117850164-A Curable resin composition, dry film, cured product, and printed wiring board 太阳控股株式会社 2024-04-09 CN disclosed
US-11884610-B2 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof SPRINGWORKS THERAPEUTICS, INC. (US) 2024-01-30 US disclosed
CN-117120930-A Laminated structure, dry film, cured product, and electronic component 太阳油墨制造株式会社 2023-11-24 CN disclosed
US-4406771-A Solvent dewaxing waxy hydrocarbon oil distillates using a combination poly di-alkyl fumarate-vinyl acetate copolymer having pendent carbon side chain length of predominantly C22 and polyalkyl(meth-)acrylate polymer dewaxing aid EXXON RESEARCH AND ENGINEERING CO. (US) 1983-09-27 US disclosed
US-4297271-A CHROMAGEN IN A DIAGNOSTIC TEST FOR FECAL BLOOD; CHROMATOGRAPHY BOEHRINGER MANNHEIM GMBH (DE) 1981-10-27 US disclosed
EP-0015655-A1 Process for coating articles by electrodeposition, compositions for use in the process and coated articles IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1980-09-17 EP disclosed
US-4219336-A HYDROGEN PEROXIDE, GUAIACONIC ACID BOEHRINGER MANNHEIM GMBH (DE) 1980-08-26 US disclosed
US-4177177-A Polymer emulsification process LEHIGH UNIVERSITY 1979-12-04 US disclosed
US-4085250-A ORGANO TITANATE LATENT CATALYST WESTINGHOUSE ELECTRIC CORPORATION (US) 1978-04-18 US disclosed
US-4068040-A CROSSLINKED POLYMERIC BINDER FUJI PHOTO FILM CO., LTD. (JA) 1978-01-10 US disclosed
US-3998983-A Resin rich epoxide-mica flexible high voltage insulation WESTINGHOUSE ELECTRIC CORPORATION (US) 1976-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11884610-B2 Crystalline solids of mek inhibitor n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof NRAS, BRAF, KSR2 ALDH1A1 3605/4885TDP1 2584/4885SMN1; SMN2 2635/4885
US-20070060756-A1 Process for the preparation of desloratadine HRH2, HRH1, HRH4 ALDH1A1 596/4885TDP1 3612/4885SMN1; SMN2 2824/4885
US-20240190815-A1 CRYSTALLINE SOLIDS OF MEK INHIBITOR N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODO--PHENYLAMINO)-BENZAMIDE AND USES THEREOF NRAS, BRAF, KSR2 ALDH1A1 3466/4885TDP1 2271/4885SMN1; SMN2 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.